scholarly journals 21. Sepsis?

2019 ◽  
Vol 3 (Supplement_1) ◽  
Author(s):  
Hannah Zacharias ◽  
Tony Chan

Abstract Introduction Sepsis is a major cause of mortality and there have been many patient safety initiatives to improve the outcome such as ‘Think Sepsis’ and ‘Sepsis 6’. It is essential to consider mimics of sepsis in those presenting with fever, particularly when there is no improvement despite antimicrobials. Macrophage activation syndrome (MAS) is a complication of uncontrolled inflammation from underlying connective tissue disease resulting in a sepsis-like condition. Delay to the detection and treatment of this condition can also result in significant morbidity and mortality. Case description We report a 28-year-old female presenting with shortness of breath, chest pain, bilateral leg swelling and fevers. Relevant past medical history included a recent diagnosis of Graves’ disease for which she had been commenced on carbimazole. On presentation CRP 53 mg/L and d-dimer 14100, chest X-ray; cardiomegally and bilateral pleural effusions, CT thoracic aorta angiogram; large pericardial effusion with maximum depth 5.9cm and compression of the cardiac chambers. Echocardiogram; preserved ejection fraction of 55-60%. The patient was commenced on intravenous antibiotics, furosemide and pericardial drain removed 1.5L.  The patient was referred to the rheumatology team on day 10. She reported episodic arthralgia, recurrent mouth ulcers, anaemia; with no evidence of haemolysis and pericardial effusion (serositis). Serology; ANA 1:1280 fine speckled pattern, dsDNA > 200, ENA positive (RNP and Smith antibodies) and low complement; C3 (0.35) and C4 (0.005), ferritin 1400, CRP 40 and ESR 62; consistent with a diagnosis of systemic lupus erythematosus (SLE). The patient was pulsed with IV methylprednisolone 500mg on Day 13 and started on prednisolone 40mg and azathioprine. Day 16; the patient developed a new pyrexia and profound hypotension resulting in admission to intensive care unit for inotropic support and escalation of antibiotics. Bedside echo revealed a small volume pericardial fluid; no tamponade, but significant new biventricular failure. Repeat ferritin was 8489, Triglycerides 5.5, LDH 331. The patient had persistent fevers and blood dyscrasias consistent with macrophage activation syndrome (MAS) with lupus myocarditis. The patient was pulsed with a further two doses of IV methylprednisolone 750mg and commenced on ciclosporin 3mg/kg. Day 18; the patient became increasingly tachycardic with increasing oxygen demands and a worsening metabolic acidosis despite renal replacement therapy. Based on the rapidity of deterioration, and lack of response to intervention the patient was transferred for extracorporeal membrane oxygenation (ECMO). Discussion This case was of interest due to the diagnostic difficulties the team faced as an underlying autoimmune condition was not initially considered. Distinguishing the need for antibiotics versus immunosuppression can be daunting for general medical teams. This case highlights the importance of involving rheumatology early in the course of a patient presenting with fever not responding to conventional therapies.  Lupus myocarditis was confirmed by cardiac biopsy after the patient went into cardiogenic shock with a LVEF 10% due to lupus myocarditis requiring ECMO support showing the severity of disease activity. The use of ECMO remains rare in our practice and there are only five centres within the UK offering this service. The patient has made an excellent response to treatment and is well maintained on mycophenolate mofetil and hydroxychloroquine; most recent echocardiogram May 2018 shows resolved effusion with normal biventricular size, ejection fraction 50 to 55%. Key learning points MAS secondary to underlying rheumatic and connective tissue disease can present with fever and features that mimic sepsis. An awareness of MAS is needed as early diagnosis and prompt initial treatment are both key factors for a favourable outcome. This case resulted in a change to clinical practice. A Trust-wide guideline on the management of MAS has now been produced to guide teams on the management of MAS in the patient with sepsis who is not improving. This case also shows the importance of collaborative team working (physicians, ICU, tertiary centre). Conflicts of interest The authors have declared no conflicts of interest.

2019 ◽  
Vol 12 (8) ◽  
pp. e229708 ◽  
Author(s):  
Marie Lind-Holst ◽  
Ulla Birgitte Hartling ◽  
Anne Estmann Christensen

We report a 12-week-old boy presenting with incomplete refractory Kawasaki disease (KD) complicated with macrophage activation syndrome (MAS). The infant presented with cerebral irritability, pain, tachypnoea and vomiting for 10 days. He did not fulfil any of the classic diagnostic criteria for KD. Pericardial effusion on echocardiography in addition to severe dilatation of the coronary arteries in combination with leucocytosis and raised acute phase reactants led to the diagnosis of incomplete KD. Treatment with intravenous immunoglobulin and aspirin was initiated but without any response. The condition was subsequently refractory to additional treatment with infliximab and high-dose methylprednisolone. His condition worsened, fulfilling the criteria for MAS. High-dose anakinra was initiated, and remission of the inflammation was achieved.


Rheumatology ◽  
2019 ◽  
Vol 58 (Supplement_4) ◽  
Author(s):  
Ethan S. Sen ◽  
Matthew Collin ◽  
Athimalaipet V. Ramanan ◽  
Rachel S. Tattersall ◽  
Jessica J. Manson

Poster presentation Tuesday 8 October Background Haemophagocytic lymphohistiocytosis (HLH)/macrophage activation syndrome (MAS) is a hyperinflammatory syndrome which can complicate sepsis, malignancy or autoimmune/autoinflammatory disease, potentially leading to critical illness and death at all ages. A previous service evaluation of children with ferritin > 10,000 μg/L, which is highly specific for HLH/MAS, reported mortality of 33% and in 44% there was no documented evidence that HLH had been considered by clinicians. The condition may present to generalists, specialists and intensivists and prompt recognition and treatment can be life-saving. A consensus for the management of HLH in older children and adults has not been defined. The aim of this ongoing project is to identify current practice and improve the evidence-base for diagnosis and treatment of HLH. Methods A national cross-specialty group was established in June 2018 including paediatric and adult specialists in rheumatology, haematology, oncology, immunology, infectious diseases, virology, nephrology and intensive care. Clinicians, scientists, pharmacists and data management experts have been incorporated. The group, which numbers over 50 professionals, has met on three occasions to set clinical and research priorities and is supported by Histiocytosis UK, a charity representing patients with HLH. Results The group agreed these priorities: To complete a retrospective service evaluation of adult patients with ferritin > 10,000 μg/L identified over a 3-year period using a standardised proforma established in the previous paediatric cohort [provisionally, this has identified over 200 adults with a mortality rate of 39%]To provide education to clinicians across the UK to improve recognition of HLH [in progress]To develop guidance for investigation of suspected HLH [in progress]To link local multi-specialty teams experienced in managing HLH to create a national network [in progress]To conduct a retrospective, observational study of the use and outcomes of anakinra treatment in HLHTo establish a national registry for HLH as part of the UK Histiocytosis Registry (UKHR) using the REDCap online portal for data collection. Patients with definite and probable HLH, including those with MAS secondary to rheumatological conditions, will be eligible for recruitment. Baseline demographic and clinical data, investigations which contribute to the HLH 2004 criteria and H score, and underlying diagnoses will constitute a minimal dataset. Treatments, and responses, and long-term follow-up data will be recorded. In addition to data collection, with the appropriate consents, biological samples will be available for genetic and histopathological analysis and cellular samples for in vitro studies. Conclusion HLH/MAS is an under-recognised condition with high mortality. A national cross-specialty, all-age collaboration has established priorities to improve clinical care and advance research. Development of a registry, with collection of biological samples, will facilitate investigation of disease pathogenesis and help to stratify patients with a view to future clinical trials. Conflicts of Interest The authors declare no conflicts of interest.


Sign in / Sign up

Export Citation Format

Share Document